Discovery and Optimization of Orally Bioavailable Phthalazone and Cinnolone Carboxylic Acid Derivatives as S1P2 Antagonists against Fibrotic Diseases.

Autor: Mammoliti O; Galapagos NV, Generaal De Wittelaan L11 A3, 2800 Mechelen, Belgium., Jansen K; Galapagos NV, Generaal De Wittelaan L11 A3, 2800 Mechelen, Belgium., El Bkassiny S; Galapagos NV, Generaal De Wittelaan L11 A3, 2800 Mechelen, Belgium., Palisse A; Galapagos NV, Generaal De Wittelaan L11 A3, 2800 Mechelen, Belgium., Triballeau N; Galapagos SASU, 102 avenue Gaston Roussel, 93230 Romainville, France., Bucher D; Galapagos SASU, 102 avenue Gaston Roussel, 93230 Romainville, France., Allart B; Galapagos NV, Generaal De Wittelaan L11 A3, 2800 Mechelen, Belgium., Jaunet A; Galapagos NV, Generaal De Wittelaan L11 A3, 2800 Mechelen, Belgium., Tricarico G; Galapagos NV, Generaal De Wittelaan L11 A3, 2800 Mechelen, Belgium., De Wachter M; Galapagos NV, Generaal De Wittelaan L11 A3, 2800 Mechelen, Belgium., Menet C; Galapagos NV, Generaal De Wittelaan L11 A3, 2800 Mechelen, Belgium., Blanc J; Galapagos NV, Generaal De Wittelaan L11 A3, 2800 Mechelen, Belgium., Letfus V; Fidelta Ltd., Prilaz Baruna Filipovića 29, ZagrebHR-10000, Croatia., Rupčić R; Fidelta Ltd., Prilaz Baruna Filipovića 29, ZagrebHR-10000, Croatia., Šmehil M; Fidelta Ltd., Prilaz Baruna Filipovića 29, ZagrebHR-10000, Croatia., Poljak T; Fidelta Ltd., Prilaz Baruna Filipovića 29, ZagrebHR-10000, Croatia., Coornaert B; Galapagos NV, Generaal De Wittelaan L11 A3, 2800 Mechelen, Belgium., Sonck K; Galapagos NV, Generaal De Wittelaan L11 A3, 2800 Mechelen, Belgium., Duys I; Galapagos NV, Generaal De Wittelaan L11 A3, 2800 Mechelen, Belgium., Waeckel L; Galapagos SASU, 102 avenue Gaston Roussel, 93230 Romainville, France., Lecru L; Galapagos SASU, 102 avenue Gaston Roussel, 93230 Romainville, France., Marsais F; Galapagos SASU, 102 avenue Gaston Roussel, 93230 Romainville, France., Jagerschmidt C; Galapagos SASU, 102 avenue Gaston Roussel, 93230 Romainville, France., Auberval M; Galapagos SASU, 102 avenue Gaston Roussel, 93230 Romainville, France., Pujuguet P; Galapagos SASU, 102 avenue Gaston Roussel, 93230 Romainville, France., Oste L; Galapagos NV, Generaal De Wittelaan L11 A3, 2800 Mechelen, Belgium., Borgonovi M; Galapagos SASU, 102 avenue Gaston Roussel, 93230 Romainville, France., Wakselman E; Galapagos SASU, 102 avenue Gaston Roussel, 93230 Romainville, France., Christophe T; Galapagos NV, Generaal De Wittelaan L11 A3, 2800 Mechelen, Belgium., Houvenaghel N; Galapagos NV, Generaal De Wittelaan L11 A3, 2800 Mechelen, Belgium., Jans M; Galapagos NV, Generaal De Wittelaan L11 A3, 2800 Mechelen, Belgium., Heckmann B; Galapagos SASU, 102 avenue Gaston Roussel, 93230 Romainville, France., Sanière L; Galapagos SASU, 102 avenue Gaston Roussel, 93230 Romainville, France., Brys R; Galapagos NV, Generaal De Wittelaan L11 A3, 2800 Mechelen, Belgium.
Jazyk: angličtina
Zdroj: Journal of medicinal chemistry [J Med Chem] 2021 Oct 14; Vol. 64 (19), pp. 14557-14586. Date of Electronic Publication: 2021 Sep 28.
DOI: 10.1021/acs.jmedchem.1c01066
Abstrakt: Idiopathic pulmonary fibrosis (IPF) is a chronic and progressive lung disease. Current treatments only slow down disease progression, making new therapeutic strategies compelling. Increasing evidence suggests that S1P2 antagonists could be effective agents against fibrotic diseases. Our compound collection was mined for molecules possessing substructure features associated with S1P2 activity. The weakly potent indole hit 6 evolved into a potent phthalazone series, bearing a carboxylic acid, with the aid of a homology model. Suboptimal pharmacokinetics of a benzimidazole subseries were improved by modifications targeting potential interactions with transporters, based on concepts deriving from the extended clearance classification system (ECCS). Scaffold hopping, as a part of a chemical enablement strategy, permitted the rapid exploration of the position adjacent to the carboxylic acid. Compound 38 , with good pharmacokinetics and in vitro potency, was efficacious at 10 mg/kg BID in three different in vivo mouse models of fibrotic diseases in a therapeutic setting.
Databáze: MEDLINE
Externí odkaz: